AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 81 min read$MCK

Rutledge Napoleon B JR sold $102K of MCK

Rutledge Napoleon B JR (SVP, Controller & CAO) sold 133 shares of MCKESSON CORP (MCK) at $764.00 ($0.10M total) on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rutledge Napoleon B JR
Published Jun 8, 2026, 6:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MCK
Neutral
high confidence
Mentioned
$MCK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The only new fact is the officer’s sale details (133 shares at $764/share) under a pre-arranged 10b5-1 plan; it does not include any company-specific operational or financial update.

02

Market read

A routine, pre-arranged insider sale is unlikely to materially change near-term trading expectations for MCK.

03

What to watch

Traders may check whether there are multiple recent insider sales or larger off-plan transactions; this filing alone is not enough.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-08; sale executed 2026-06-05.

Background

The article summarizes an SEC Form 4 insider transaction for McKesson (MCK) filed on EDGAR.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

SEC Form 4 shows Mckesson officer Rutledge sold 133 shares at $764/share under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone.

Evidence & confidence

The disclosure is a small, pre-arranged 10b5-1 sale by an officer; it does not indicate new company fundamentals or guidance.

Market effects

Sector

No sector read-through; this is a single, small insider transaction with no stated corporate event.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even 10b5-1 sales can coincide with private information, but the article provides no evidence beyond the plan designation.

Key entities

  • issuer
    MCK

    McKesson Corp; subject of the Form 4 insider transaction disclosure.

  • insider
    Rutledge Napoleon B JR

    SVP, Controller & CAO who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MCK insider trading history →

Related articles

OCT 10
$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

hoodline.com2 min
OCT 9
$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

finance.yahoo.com2 min
OCT 8
$MCKHighAI 9/10

McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

healthcare-digital.com3 min
OCT 7
$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

finance.yahoo.com2 min
OCT 7
$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.

finchannel.com2 min